Compare DTSS & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTSS | ERNA |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 7.7M |
| IPO Year | 2015 | 2021 |
| Metric | DTSS | ERNA |
|---|---|---|
| Price | $0.91 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.7K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | 20.10 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $71,616,820.00 | $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 198.70 | ★ 755.88 |
| 52 Week Low | $0.64 | $0.15 |
| 52 Week High | $2.70 | $3.00 |
| Indicator | DTSS | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 33.60 |
| Support Level | $0.81 | $0.27 |
| Resistance Level | $0.98 | $0.40 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 67.87 | 69.86 |
Datasea Inc is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.